Ligand Pharmaceuticals Bilan de santé
Santé financière contrôle des critères 6/6
Ligand Pharmaceuticals possède un total de capitaux propres de $775.2M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $866.4M et de $91.2M. L'EBIT de Ligand Pharmaceuticals est $8.0M ce qui fait que son ratio de couverture des intérêts -1.1. Elle dispose de liquidités et de placements à court terme de $226.9M.
Informations clés
0%
Ratio d'endettement
US$0
Dette
| Ratio de couverture des intérêts | -1.1x |
| Argent liquide | US$226.93m |
| Fonds propres | US$775.20m |
| Total du passif | US$91.21m |
| Total des actifs | US$866.41m |
Mises à jour récentes de la santé financière
We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
May 29
These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well
Jan 26We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
Oct 21Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly
Jun 27We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt With Ease
Mar 17Recent updates
Market Participants Recognise Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Earnings
Oct 31Ligand Pharmaceuticals: Solid Performer Performing Solidly
Jul 29Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Jul 18Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?
Jun 29Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%
May 23Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio
Apr 30Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar
Dec 19Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?
Jun 14We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
May 29Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?
May 07These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well
Jan 26We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
Oct 21Ligand Pharmaceuticals: Struggling Along
Sep 25Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%
Aug 11Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly
Jun 27Ligand Pharmaceuticals: Moving Parts Keep Moving
Mar 29We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt With Ease
Mar 17Analyse de la situation financière
Passif à court terme: Les actifs à court terme de LGND ( $312.3M ) dépassent ses passifs à court terme ( $18.6M ).
Passif à long terme: Les actifs à court terme de LGND ( $312.3M ) dépassent ses passifs à long terme ( $72.6M ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: LGND est sans dette.
Réduire la dette: LGND n'a aucune dette par rapport à il y a 5 ans, lorsque son ratio d'endettement était 62.5%.
Couverture de la dette: LGND n'a pas de dette, elle n'a donc pas besoin d'être couverte par le flux de trésorerie opérationnel.
Couverture des intérêts: LGND n'a aucune dette, par conséquent la couverture des paiements d'intérêts n'est pas un problème.